<?xml version='1.0' encoding='utf-8'?>
<document id="28130599"><sentence text="Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna." /><sentence text="We aimed to investigate the efficacy of interferon and ribavirin-free sofosbuvir/ledipasvir (SOF/LDV) and ritonavir boosted paritaprevir/ombitasvir with or without dasabuvir (2D/3D) regimens in a real-life cohort of human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfected patients"><entity charOffset="55-64" id="DDI-PubMed.28130599.s2.e0" text="ribavirin" /><entity charOffset="70-80" id="DDI-PubMed.28130599.s2.e1" text="sofosbuvir" /><entity charOffset="81-91" id="DDI-PubMed.28130599.s2.e2" text="ledipasvir" /><entity charOffset="93-96" id="DDI-PubMed.28130599.s2.e3" text="SOF" /><entity charOffset="97-100" id="DDI-PubMed.28130599.s2.e4" text="LDV" /><entity charOffset="106-115" id="DDI-PubMed.28130599.s2.e5" text="ritonavir" /><entity charOffset="124-136" id="DDI-PubMed.28130599.s2.e6" text="paritaprevir" /><entity charOffset="137-147" id="DDI-PubMed.28130599.s2.e7" text="ombitasvir" /><entity charOffset="164-173" id="DDI-PubMed.28130599.s2.e8" text="dasabuvir" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e0" e2="DDI-PubMed.28130599.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e0" e2="DDI-PubMed.28130599.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e0" e2="DDI-PubMed.28130599.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e0" e2="DDI-PubMed.28130599.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e0" e2="DDI-PubMed.28130599.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e0" e2="DDI-PubMed.28130599.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e0" e2="DDI-PubMed.28130599.s2.e6" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e0" e2="DDI-PubMed.28130599.s2.e7" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e0" e2="DDI-PubMed.28130599.s2.e8" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e1" e2="DDI-PubMed.28130599.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e1" e2="DDI-PubMed.28130599.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e1" e2="DDI-PubMed.28130599.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e1" e2="DDI-PubMed.28130599.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e1" e2="DDI-PubMed.28130599.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e1" e2="DDI-PubMed.28130599.s2.e6" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e1" e2="DDI-PubMed.28130599.s2.e7" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e1" e2="DDI-PubMed.28130599.s2.e8" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e2" e2="DDI-PubMed.28130599.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e2" e2="DDI-PubMed.28130599.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e2" e2="DDI-PubMed.28130599.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e2" e2="DDI-PubMed.28130599.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e2" e2="DDI-PubMed.28130599.s2.e6" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e2" e2="DDI-PubMed.28130599.s2.e7" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e2" e2="DDI-PubMed.28130599.s2.e8" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e3" e2="DDI-PubMed.28130599.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e3" e2="DDI-PubMed.28130599.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e3" e2="DDI-PubMed.28130599.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e3" e2="DDI-PubMed.28130599.s2.e6" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e3" e2="DDI-PubMed.28130599.s2.e7" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e3" e2="DDI-PubMed.28130599.s2.e8" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e4" e2="DDI-PubMed.28130599.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e4" e2="DDI-PubMed.28130599.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e4" e2="DDI-PubMed.28130599.s2.e6" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e4" e2="DDI-PubMed.28130599.s2.e7" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e4" e2="DDI-PubMed.28130599.s2.e8" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e5" e2="DDI-PubMed.28130599.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e5" e2="DDI-PubMed.28130599.s2.e6" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e5" e2="DDI-PubMed.28130599.s2.e7" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e5" e2="DDI-PubMed.28130599.s2.e8" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e6" e2="DDI-PubMed.28130599.s2.e6" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e6" e2="DDI-PubMed.28130599.s2.e7" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e6" e2="DDI-PubMed.28130599.s2.e8" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e7" e2="DDI-PubMed.28130599.s2.e7" /><pair ddi="false" e1="DDI-PubMed.28130599.s2.e7" e2="DDI-PubMed.28130599.s2.e8" /></sentence><sentence text=" The study focused on efficacy, need for changes in antiretroviral therapy (ART) due to drug-drug interaction (DDI), and treatment-associated changes in liver stiffness" /><sentence text="" /><sentence text="In this study 36 patients (n = 21 SOF/LDV and n = 15 2D/3D) were retrospectively analyzed"><entity charOffset="34-42" id="DDI-PubMed.28130599.s5.e0" text="SOF" /><entity charOffset="38-46" id="DDI-PubMed.28130599.s5.e1" text="LDV" /><pair ddi="false" e1="DDI-PubMed.28130599.s5.e0" e2="DDI-PubMed.28130599.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28130599.s5.e0" e2="DDI-PubMed.28130599.s5.e1" /></sentence><sentence text=" Depending on the genotype the following treatment regimens were used: HCV genotype (GT)-1: either SOF/LDV or 3D, no patient with HCV-GT2 was included, HCV-GT3: SOF/LDV, HCV-GT4: 2D"><entity charOffset="99-101" id="DDI-PubMed.28130599.s6.e0" text="SOF" /><entity charOffset="161-163" id="DDI-PubMed.28130599.s6.e1" text="SOF" /><entity charOffset="103-105" id="DDI-PubMed.28130599.s6.e2" text="LDV" /><entity charOffset="165-167" id="DDI-PubMed.28130599.s6.e3" text="LDV" /><pair ddi="false" e1="DDI-PubMed.28130599.s6.e0" e2="DDI-PubMed.28130599.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28130599.s6.e0" e2="DDI-PubMed.28130599.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28130599.s6.e0" e2="DDI-PubMed.28130599.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28130599.s6.e0" e2="DDI-PubMed.28130599.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28130599.s6.e2" e2="DDI-PubMed.28130599.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28130599.s6.e2" e2="DDI-PubMed.28130599.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28130599.s6.e2" e2="DDI-PubMed.28130599.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28130599.s6.e1" e2="DDI-PubMed.28130599.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28130599.s6.e1" e2="DDI-PubMed.28130599.s6.e3" /></sentence><sentence text="" /><sentence text="Approximately one third (35" /><sentence text="3%) of patients were treatment-experienced and 13" /><sentence text="9% had cirrhosis" /><sentence text=" Antiretroviral therapy had to be changed in 38" /><sentence text="1% of SOF/LDV and 60% of 2D/3D patients prior to anti-HCV treatment due to expected DDIs"><entity charOffset="6-8" id="DDI-PubMed.28130599.s12.e0" text="SOF" /><entity charOffset="10-12" id="DDI-PubMed.28130599.s12.e1" text="LDV" /><pair ddi="false" e1="DDI-PubMed.28130599.s12.e0" e2="DDI-PubMed.28130599.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28130599.s12.e0" e2="DDI-PubMed.28130599.s12.e1" /></sentence><sentence text=" We observed sustained virologic response (SVR) rates of 100% in patients treated with SOF/LDV (19/19) and 2D/3D (14/14)"><entity charOffset="87-89" id="DDI-PubMed.28130599.s13.e0" text="SOF" /><entity charOffset="91-93" id="DDI-PubMed.28130599.s13.e1" text="LDV" /><pair ddi="false" e1="DDI-PubMed.28130599.s13.e0" e2="DDI-PubMed.28130599.s13.e0" /><pair ddi="false" e1="DDI-PubMed.28130599.s13.e0" e2="DDI-PubMed.28130599.s13.e1" /></sentence><sentence text=" One 2D/3D patient was lost to follow-up, while two SOF/LDV patients died during therapy from non-treatment-related causes"><entity charOffset="52-54" id="DDI-PubMed.28130599.s14.e0" text="SOF" /><entity charOffset="56-58" id="DDI-PubMed.28130599.s14.e1" text="LDV" /><pair ddi="false" e1="DDI-PubMed.28130599.s14.e0" e2="DDI-PubMed.28130599.s14.e0" /><pair ddi="false" e1="DDI-PubMed.28130599.s14.e0" e2="DDI-PubMed.28130599.s14.e1" /></sentence><sentence text=" They were excluded from the analysis" /><sentence text=" Between baseline and follow-up liver stiffness decreased from 11" /><sentence text="4 to 8" /><sentence text="3 kPa (p = 0" /><sentence text="008) and from 8" /><sentence text="1 to 5" /><sentence text="7 kPa (p = 0" /><sentence text="001) in SOF/LDV and 2D/3D patients, respectively"><entity charOffset="8-10" id="DDI-PubMed.28130599.s22.e0" text="SOF" /><entity charOffset="12-14" id="DDI-PubMed.28130599.s22.e1" text="LDV" /><pair ddi="false" e1="DDI-PubMed.28130599.s22.e0" e2="DDI-PubMed.28130599.s22.e0" /><pair ddi="false" e1="DDI-PubMed.28130599.s22.e0" e2="DDI-PubMed.28130599.s22.e1" /></sentence><sentence text="" /><sentence text="We confirmed the excellent HCV eradication rates &gt;95% in a real-life cohort of HIV/HCV coinfected patients treated with SOF/LDV and 2D/3D"><entity charOffset="120-122" id="DDI-PubMed.28130599.s24.e0" text="SOF" /><entity charOffset="124-126" id="DDI-PubMed.28130599.s24.e1" text="LDV" /><pair ddi="false" e1="DDI-PubMed.28130599.s24.e0" e2="DDI-PubMed.28130599.s24.e0" /><pair ddi="false" e1="DDI-PubMed.28130599.s24.e0" e2="DDI-PubMed.28130599.s24.e1" /></sentence><sentence text=" We observed no HCV relapse or breakthrough" /><sentence text=" More patients treated with 2D/3D required a change in ART than patients treated with SOF/LDV"><entity charOffset="86-88" id="DDI-PubMed.28130599.s26.e0" text="SOF" /><entity charOffset="90-92" id="DDI-PubMed.28130599.s26.e1" text="LDV" /><pair ddi="false" e1="DDI-PubMed.28130599.s26.e0" e2="DDI-PubMed.28130599.s26.e0" /><pair ddi="false" e1="DDI-PubMed.28130599.s26.e0" e2="DDI-PubMed.28130599.s26.e1" /></sentence><sentence text=" Additionally, HCV eradication led to a rapid decline in liver stiffness" /><sentence text="" /></document>